| Drug ID: | Drug181 |
|---|---|
| Drug Name: | Steroids |
| CID: | 139082353 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05702879, , NCT03460847 |
| Molecular Formula: | C26H44N2O |
| Molecular Weight: | 400.6 g/mol |
| Isomeric SMILES: | C[C@H]([C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CC=C4[C@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C(=O)C |
| Synonyms: | Steroid; 3alpha-Dimethylamino-20-(N-methylacetamido)pregn-5-ene; Steroids; Steroid Compound; Arnolds, Gear, Gym Candy, Juice, Pumpers, Roids, Stackers, Weight Gainers |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1299 | 139082353 | Steroids | 1576 | CYP3A4 | Homo sapiens (human) | 15955870 | Steroids results in increased expression of CYP3A4 |
| dt1300 | 139082353 | Steroids | 2554 | GABRA1 | Rattus norvegicus (Norway rat) | 18275132 | GABRA1 protein mutant form results in decreased susceptibility to steroids analog|steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1301 | 139082353 | Steroids | 2561 | GABRB2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1302 | 139082353 | Steroids | 2566 | GABRG2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1303 | 139082353 | Steroids | 3565 | IL4 | Rattus norvegicus (Norway rat) | 10685002 | Steroids results in decreased expression of IL4 protein |
| dt1304 | 139082353 | Steroids | 5069 | PAPPA | Mus musculus (house mouse) | 20130263 | PAPPA protein affects the chemical synthesis of steroids |
| dt1305 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 20021565 | POMC protein affects the reaction [ethanol results in increased abundance of steroids] |
| dt1306 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 1668613 | POMC protein alternative form affects the abundance of steroids |
| dt1307 | 139082353 | Steroids | 103142 | Rdh9 | Mus musculus (house mouse) | 17270348 | RDH9 protein results in increased metabolism of steroids |
| dt1308 | 139082353 | Steroids | 6770 | STAR | Rattus norvegicus (Norway rat) | 12699903 | [manganese chloride results in decreased expression of STAR protein] which results in decreased chemical synthesis of steroids |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05702879 | Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success | NULL | UNKNOWN | Insel Gruppe AG, University Hospital Bern | Ulcerative Colitis | DRUG: Ozanimod|DRUG: TNF Inhibitor|DRUG: Steroids… | Details |
| NCT05284136 | Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease | PHASE2|PHASE3 | UNKNOWN | Assistance Publique - Hôpitaux de Paris | Crohn Disease | DIETARY_SUPPLEMENT: Crohn's disease exclusion die… | Details |
| NCT04999228 | Top Down Versus Step up in Pediatric Ulcerative Colitis | PHASE4 | RECRUITING | Children's Hospital of Fudan University | Ulcerative Colitis|Infliximab|Children | DRUG: Infliximab|DRUG: Corticosteroids | Details |
| NCT04564638 | Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids | NULL | COMPLETED | Tampere University Hospital | Ulcerative Colitis | DRUG: Corticosteroid | Details |
| NCT03942861 | Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. | NULL | UNKNOWN | Copenhagen University Hospital at Herlev | Ulcerative Colitis|Ultrasound Therapy; Complicati… | DRUG: Solu-Medrol | Details |
| NCT03833596 | Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) | PHASE4 | TERMINATED | McMaster University | Crohn's Disease | DRUG: Prednisone|DIETARY_SUPPLEMENT: Exclusive En… | Details |
| NCT03460847 | Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa | NULL | COMPLETED | Medical University of Graz | Colitis, Ulcerative | DRUG: Steroids | Details |
| NCT02922374 | Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis | PHASE1|PHASE2 | UNKNOWN | Jinling Hospital, China | Acute Severe Colitis (ASC) | DRUG: corticosteroids | Details |
| NCT02665845 | Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). | PHASE3 | COMPLETED | Centre Hospitalier Universitaire de Saint Etienne | Ulcerative Colitis | DRUG: 5-ASA|DRUG: Corticosteroids | Details |
| NCT02619552 | Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease | NULL | COMPLETED | University of Maryland, Baltimore | Crohn's Disease|IBD | DRUG: Anti-TNF|DRUG: Anti-TNF|DRUG: Steroids | Details |
| NCT02425852 | A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis | PHASE4 | COMPLETED | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Ulcerative Colitis | DRUG: Azathioprine|DRUG: Infliximab|DRUG: Prednis… | Details |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | PHASE4 | TERMINATED | Icahn School of Medicine at Mount Sinai | Crohn's Disease | DRUG: Prednisone|DRUG: Placebo|DRUG: Vedolizumab | Details |
| NCT02033408 | Manipulating the Microbiome in IBD by Antibiotics and FMT | NA | COMPLETED | Shaare Zedek Medical Center | Exacerbation of Ulcerative Colitis|Ulcerative Col… | DRUG: AB (antibiotics)|DRUG: CS (corticosteroids)… | Details |
| NCT01941589 | Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis | PHASE4 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DRUG: oral 5-ASA+/-topical 5-ASA+IV corticosteroi… | Details |
| NCT01536535 | Predicting Response to Standardized Pediatric Colitis Therapy | PHASE4 | COMPLETED | Connecticut Children's Medical Center | Ulcerative Colitis | DRUG: Mesalazine|DRUG: IV Corticosteroid|DRUG: Or… | Details |
| NCT00702611 | Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DEVICE: Granulocyte Monocyte Apheresis (GMA-Apher… | Details |
| NCT00672763 | Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease | PHASE4 | WITHDRAWN | Imperial College London | Crohn's Disease | DRUG: Colecalciferol D3 (Vigantol Oil)|DRUG: Medi… | Details |
| NCT00514982 | Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome | PHASE2 | WITHDRAWN | National Institute of Allergy and Infectious Diseases (NIAID) | Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymph… | DRUG: Mesalamine|DRUG: Infliximab|DRUG: Corticost… | Details |
| NCT00269438 | New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: 5 ASA, enemas, suppositories, corticosteroi… | Details |
| NCT00265772 | Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | PHASE4 | UNKNOWN | Hôpital Necker-Enfants Malades | Crohn's Disease|Pediatric | DRUG: MODULEN IBD (R) (specific Enteral Nutrition… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's d…
PMID: 16265778
Year: 2005
Relationship Type:
Treatment
Score: 8.1
Resveratrol, a naturally occurring polyphenol has received significant attention as a potent anti-inflammatory agent. Inflammatory bowel disease (IB…
New steroids for IBD: progress report
PMID: 12117876
Year: 2002
Relationship Type:
Association
Score: 8.1
Not found
Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's d…
PMID: 11720327
Year: 2001
Relationship Type:
Association
Score: 8.1
Not found
Corticosteroids impair intestinal epithelial wound repair mechanisms in vitro
PMID: 11521988
Year: 2001
Relationship Type:
Mechanism
Score: 8.1
Endogenously formed nitrogen and oxygen free radicals are believed to be involved in human cancer etiology. Plasma nitrate/nitrite originates from …
Effect of steroids in an IBD model
PMID: 8280826
Year: 1993
Relationship Type:
Association
Score: 8.1
Not found
Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Re…
PMID: 40568347
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Ciclosporin and infliximab have equal short-term efficacy in treating acute severe ulcerative colitis (ASUC). However, data about long-te…
Epidemiology and Steroid Dependency Reduction in Crohn's Disease During the Bio…
PMID: 40549269
Year: 2025
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Crohn's disease (CD), a subtype of inflammatory bowel disease, is a growing health concern. In this study, we examined the influence of…
Perspectives in clinical research on Azathioprine for steroid-dependent ulcerat…
PMID: 40201324
Year: 2025
Relationship Type:
Treatment
Score: 6.5
This study explores the application of Azathioprine in the treatment of ulcerative colitis (UC) and the challenges associated with its long-term use.…
Evaluation of Acute Severe Ulcerative Colitis Predictors for Steroid Therapy Re…
PMID: 40188169
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: One-third of patients presenting with acute severe ulcerative colitis (ASUC) are steroid-refractory and require either colectomy or rescu…
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients …
PMID: 40168091
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) therapy in patients with moderate-to-s…
Steroid constituents of Solidago canadensis alleviate LPS-induced inflammation …
PMID: 40113066
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammation is a major risk factor for a variety of human diseases, such as sepsis, Inflammatory Bowel Disease (IBD) and also major cardiovascular d…
Delayed Corticosteroid Treatment for Patients Requiring Hospitalization for Acu…
PMID: 39948278
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: While corticosteroids are not recommended for maintenance of remission in inflammatory bowel disease (IBD), they are quite effective for …
Rapid and Sustained Resolution of Peristomal Pyoderma Gangrenosum With Aerosol …
PMID: 39836006
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Peristomal pyoderma gangrenosum (PPG) is a non-infectious neutrophilic dermatosis most commonly seen in the context of ostomies in inflam…
[Assessment of corticosteroid use as a marker of quality-of-care in the managem…
PMID: 39825810
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Despite advancements in therapeutic strategies, corticosteroids continue to play a role in inducing remission in Inflammatory Bowel Dis…
Anti-PD1-/PDL1-induced chronic intestinal pseudo-obstruction: three cases treat…
PMID: 39751892
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Immune checkpoint inhibitors (ICI), i.e., anti-PD1/PDL1 and anti-CTLA-4, have reshaped the prognosis of many cancers. Increased use of ICI has led to…
Investigating the impact of steroid dependence on gastrointestinal surgical out…
PMID: 39587092
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Although corticosteroids are an important treatment for inflammatory bowel disease (IBD) patients, many subjects develop dependence, leading to serio…
Analysis of excessive corticosteroid use as an indicator of poor quality of car…
PMID: 39526727
Year: 2024
Relationship Type:
Treatment
Score: 6.5
AIM: To evaluate the clinical impact of corticosteroids (CS) overuse in inflammatory bowel disease (IBD) patients. Excessive use of CS could delay mo…
Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecul…
PMID: 39419764
Year: 2025
Relationship Type:
Clinical Trial
Score: 6.5
BACKGROUND AND AIMS: This systematic review aims to elucidate the use of corticosteroids in randomized clinical trials (RCTs) evaluating biologics an…
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory B…
PMID: 39243391
Year: 2025
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND AND AIMS: Corticosteroids are widely used in managing inflammatory bowel disease (IBD). While adverse events (AEs) of corticosteroids are …
Healthcare Utilization Patterns and Excessive Steroid Use in Late Adolescence A…
PMID: 39130756
Year: 2023
Relationship Type:
Association
Score: 6.5
BACKGROUND AND AIMS: Late adolescents and young adults (AYA) with inflammatory bowel disease (IBD) are a vulnerable population as they transition to …